Cassava Sciences, Inc. – NASDAQ:SAVA

Add to watchlist

$2.2

-0.30

-12.01%

Market closed

Open in 3 days

-78.28%

month

-78.28%

quarter

-88.89%

year

Market Cap	124.60M
Enterprise value	739.85M

P/E	-12.25
EV/Sales	N/A
EV/EBITDA	-10.03
Price/Sales	N/A
Price/Book	4.13
PEG ratio	0.09
EPS	-1.16

Revenue	N/A
EBITDA	-98.71M
Income	-47.90M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Cassava Sciences, Inc. (NASDAQ:SAVA): Profit margin
Jun 2023	0	-26.37M
Sep 2023	0	-25.65M
Dec 2023	2.34M	-20.91M	-890.93%
Mar 2024	0	25.04M

Cassava Sciences Financials Estimate

Q Y

Cassava Sciences, Inc. (NASDAQ:SAVA): Analyst Estimates
2025	100M	17.75M	17.75%
2026	0	-67.2M
2027	6.4M	-31.86M	-497.94%
2028	72.4M	10.90M	15.06%

Analysts Price target
Financials & Ratios estimates

Cassava Sciences, Inc. (NASDAQ:SAVA): Debt to assets
Jun 2023	197248000	17.89M	9.07%
Sep 2023	172529000	17.41M	10.09%
Dec 2023	151663000	14.19M	9.36%
Mar 2024	155718000	77.12M	49.53%

Cassava Sciences, Inc. (NASDAQ:SAVA): Cash Flow
Jun 2023	-19.92M	6K	889K
Sep 2023	-26.53M	-22K	464K
Dec 2023	-22.31M	-41K	1.14M
Mar 2024	-19.12M	0	22.16M

Cassava Sciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Cassava Sciences, Inc. (NASDAQ:SAVA): Employee count
Aug 2023	26
Sep 2023	26
Oct 2023	26
Nov 2023	26
Dec 2023	26
Jan 2024	26
Feb 2024	26
Mar 2024	29
Apr 2024	29
May 2024	29
Jun 2024	29
Jul 2024	29

Cassava Sciences
Hedge Funds Holdings Q2 2022

100.00% 0.00%

of SAVA is owned by hedge funds

137 -10

hedge funds hold SAVA stock

9.67M -531.69K

shares is hold by hedge funds

SAVA hedge funds holdings changes

Cassava Sciences
Insider Trading

Cassava Sciences, Inc. (NASDAQ:SAVA): Insider trades (number of shares)
Period	Buy	Sel
Nov 2024	0	65800

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	29 Nov 2024	KUPIEC JAMES WILLIAM officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	4,000	$3.87	$15,480
Option	29 Nov 2024	SCHOEN ERIC officer: Chief Fi..	Common Stock	50,000	$1.18	$59,000
Sale	29 Nov 2024	SCHOEN ERIC officer: Chief Fi..	Common Stock	59,800	$3.86	$230,828
Option	29 Nov 2024	SCHOEN ERIC officer: Chief Fi..	Stock Option (Right to Buy)	50,000	$1.18	$59,000
Sale	29 Nov 2024	SCHOEN ERIC officer: Chief Fi..	Common Stock	2,000	$3.82	$7,640
Option	26 Apr 2024	ROBERTSON SANFORD director director	Common Stock	69,000	$22	$1,518,000
Option	26 Apr 2024	ROBERTSON SANFORD director director	Common Stock Warrant	46,000	$33	$1,518,000
Option	23 Apr 2024	BARRY RICHARD director director	Common Stock	176,085	$22	$3,873,870
Option	23 Apr 2024	BARRY RICHARD director director	Common Stock Warrant	117,390	$33	$3,873,870
Option	18 Apr 2024	KUPIEC JAMES WILLIAM officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	1,500	$22	$33,000

SAVA insider trading transactions

Cassava Sciences
Earnings Call Transcripts

Quarter	Transcript
Q3 2018 29 Oct 2018	Q3 2018 Earnings Call Transcript
Q3 2014 31 Oct 2014	Q3 2014 Earnings Call Transcript
Q2 2014 6 Aug 2014	Q2 2014 Earnings Call Transcript

SAVA earnings call transcripts

Cassava Sciences
Executives

Insider	Age	Compensation
Mr. Remi Barbier (1960) Founder, Chairman, Pres & Chief Executive Officer	65	$936,120
Dr. Nadav Friedmann (1943) Chief Medical Officer & Director	82	$345,000
Mr. Eric J. Schoen (1968) Chief Financial Officer	57	$251,930

Cassava Sciences
Latest News

Saturday, 28 December 2024
18:43	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA	accesswire.com
18:01	Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA	accesswire.com
09:18	SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit	prnewswire.com
Friday, 27 December 2024
22:50	CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA	prnewswire.com
17:08	Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA	accesswire.com
16:30	Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline	accesswire.com
15:56	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	prnewswire.com
14:15	Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky	accesswire.com
14:02	Class Action Announcement for Cassava Sciences, Inc. (SAVA): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.	globenewswire.com
14:00	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA	accesswire.com
12:15	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA	accesswire.com
11:51	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA	globenewswire.com
07:30	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA	accesswire.com
07:00	SAVA Shareholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!	accesswire.com
05:45	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA	prnewswire.com
00:15	Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky	accesswire.com
Thursday, 26 December 2024
19:47	SAVA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.	businesswire.com
19:00	CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA	accesswire.com
16:00	SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	globenewswire.com
12:45	Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA	accesswire.com
12:30	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	accesswire.com
12:00	Investors who lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA	accesswire.com
11:15	Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA	accesswire.com
10:45	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA	accesswire.com
10:15	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA	accesswire.com
09:45	Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA	accesswire.com
09:15	Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA	accesswire.com
08:45	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA	accesswire.com
08:15	Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline	accesswire.com
08:00	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA	accesswire.com

Ideas & Opinions

Seeking Alpha 10 May 2024

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
Seeking Alpha 5 Dec 2023

Alzheimer's Disease Drug Development: Another Lost Year
Seeking Alpha 20 Nov 2023

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year
Seeking Alpha 30 Oct 2023

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
Seeking Alpha 11 Oct 2023

Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet
Seeking Alpha 6 Sep 2023

Week Of 08/28 Notable Insider Buys
Seeking Alpha 29 Aug 2023

Week Of 08/21 Notable Insider Buys
Seeking Alpha 14 Aug 2023

Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics
Seeking Alpha 10 Aug 2023

Cassava Sciences: CMS Data Promising But Many Red Flags Remain; Hold
Seeking Alpha 28 Jul 2023

Eli Lilly: There Is No Logic To This Over Optimism

Frequently Asked Questions (FAQ)

What's the price of Cassava Sciences stock today?

One share of Cassava Sciences stock can currently be purchased for approximately $2.2.
When is Cassava Sciences's next earnings date?

Unfortunately, Cassava Sciences's (SAVA) next earnings date is currently unknown.
Does Cassava Sciences pay dividends?

No, Cassava Sciences does not pay dividends.
How much money does Cassava Sciences make?

Cassava Sciences has a market capitalization of 124.60M.
What is Cassava Sciences's stock symbol?

Cassava Sciences, Inc. is traded on the NASDAQ under the ticker symbol "SAVA".
What is Cassava Sciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Cassava Sciences?

Shares of Cassava Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Cassava Sciences's key executives?
Cassava Sciences's management team includes the following people:
- Mr. Remi Barbier Founder, Chairman, Pres & Chief Executive Officer(age: 65, pay: $936,120)
- Dr. Nadav Friedmann Chief Medical Officer & Director(age: 82, pay: $345,000)
- Mr. Eric J. Schoen Chief Financial Officer(age: 57, pay: $251,930)
Is Cassava Sciences founder-led company?

Yes, Cassava Sciences is a company led by its founder Mr. Remi Barbier.
How many employees does Cassava Sciences have?

As Jul 2024, Cassava Sciences employs 29 workers.
When Cassava Sciences went public?

Cassava Sciences, Inc. is publicly traded company for more then 25 years since IPO on 14 Jul 2000.
What is Cassava Sciences's official website?

The official website for Cassava Sciences is cassavasciences.com.
Where are Cassava Sciences's headquarters?

Cassava Sciences is headquartered at 7801 North Capital of Texas Highway, Austin, TX.
How can i contact Cassava Sciences?

Cassava Sciences's mailing address is 7801 North Capital of Texas Highway, Austin, TX and company can be reached via phone at +51 25012444.

Cassava Sciences, Inc.

cassavasciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

+51 25012444

7801 North Capital of Texas Highway
Austin, TX 78731

CIK: 0001069530
ISIN: US14817C1071
CUSIP: 14817C107